We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market this year for hereditary angioedema, acute lymphoblastic leukemia (ALL), and aromatic L-amino acid decarboxylase (AADC) deficiency.
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- An update on Food and Drug Administration (FDA) Accelerated Approvals.
- A spotlight on a nonopioid acute pain drug in the late-stage pipeline, and what’s expected following the first FDA approval for nonalcoholic steatohepatitis (NASH) earlier this year.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
You may also be interested in:
Q2 2024 Legislative Activity Update
Q2 2024 CarelonRx DrugInsights
Our Evidence-Based Formulary Development Process
